-
1
-
-
0031603035
-
Use of calcium channel blockers in hypertension
-
[1] Conlin P.R., Williams G.H., Use of calcium channel blockers in hypertension, Adv. Intern. Med. 43 (1998) 533 562.
-
(1998)
Adv. Intern. Med.
, vol.43
, pp. 533
-
-
Conlin, P.R.1
Williams, G.H.2
-
2
-
-
2642642140
-
Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade
-
[2] Noll G., Luscher T.F., Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade, Cardiology Suppl. 1 89 (1998) 10-15.
-
(1998)
Cardiology Suppl.
, vol.89
, Issue.SUPPL. 1
, pp. 10-15
-
-
Noll, G.1
Luscher, T.F.2
-
3
-
-
0030892635
-
Pharmacological aspects of calcium channel blockers
-
[3] Scholz H., Pharmacological aspects of calcium channel blockers, Cardiovasc. Drugs Ther. Suppl. 3 10 (1997) 869 872.
-
(1997)
Cardiovasc. Drugs Ther. Suppl.
, vol.3-10
, pp. 869
-
-
Scholz, H.1
-
4
-
-
0031466388
-
Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker
-
[4] Clozel J.P., Ertel E.A., Ertel S.I., Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker, J. Hypertens. Suppl. 15 (5) (1997) S17-S25.
-
(1997)
J. Hypertens. Suppl.
, vol.15
, Issue.5
-
-
Clozel, J.P.1
Ertel, E.A.2
Ertel, S.I.3
-
5
-
-
0030574227
-
Pharmacologic and therapeutic differences among calcium channel antagonists: Profile of mibefradil, a new calcium antagonist
-
[5] Triggle D.J., Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist, Am. J. Cardiol. 78 (9A) (1996) 7-12.
-
(1996)
Am. J. Cardiol.
, vol.78
, Issue.9 A
, pp. 7-12
-
-
Triggle, D.J.1
-
7
-
-
0031971534
-
Mibefradil, a pharmacologically distinct calcium antagonist
-
[7] Ernst M.E., Kelly M.W., Mibefradil, a pharmacologically distinct calcium antagonist, Pharmacotherapy 18 (3) (1998) 463 485.
-
(1998)
Pharmacotherapy
, vol.18
, Issue.3
, pp. 463
-
-
Ernst, M.E.1
Kelly, M.W.2
-
8
-
-
0029609806
-
Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist
-
[8] Petrie J.R., Glen S.K., MacMahon M., Crome R., Meredith P.A., Elliott H.L., Reid J.L., Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist, J. Hypertens. 13 (12 Pt 2) (1995) 1842-1846.
-
(1995)
J. Hypertens.
, vol.13
, Issue.12 PT 2
, pp. 1842-1846
-
-
Petrie, J.R.1
Glen, S.K.2
MacMahon, M.3
Crome, R.4
Meredith, P.A.5
Elliott, H.L.6
Reid, J.L.7
-
9
-
-
0030063405
-
Nonlinear pharmacokinetics of mibefradil in the dog
-
[9] Skerjanec A., Tawfik S., Tam Y.K., Nonlinear pharmacokinetics of mibefradil in the dog, J. Pharm. Sci. 85 (2) (1996) 189-192.
-
(1996)
J. Pharm. Sci.
, vol.85
, Issue.2
, pp. 189-192
-
-
Skerjanec, A.1
Tawfik, S.2
Tam, Y.K.3
-
10
-
-
0030694359
-
Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris
-
[10] Brogden R.N., Markham A., Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris, Drugs 54 (5) (1997) 774-793.
-
(1997)
Drugs
, vol.54
, Issue.5
, pp. 774-793
-
-
Brogden, R.N.1
Markham, A.2
-
11
-
-
0029885746
-
Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Mibefradil International Study Group
-
[11] Bernink P.J., Prager G., Schelling A., Kobrin I., Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group, Hypertension 27 (3 Pt 1) (1996) 426-432.
-
(1996)
Hypertension
, vol.27
, Issue.3 PT 1
, pp. 426-432
-
-
Bernink, P.J.1
Prager, G.2
Schelling, A.3
Kobrin, I.4
-
12
-
-
0031437326
-
Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition
-
[12] Buhler F.R., Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition, J. Hypertens. Suppl. 15 (5) (1997) S3-S7.
-
(1997)
J. Hypertens. Suppl.
, vol.15
, Issue.5
-
-
Buhler, F.R.1
-
13
-
-
0027967663
-
The Ca( + + )-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca + + channels
-
[13] Mehrke G., Zong X.G., Flockerzi V., Hofmann F., The Ca( + + )-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca + + channels, J. Pharmacol. Exp. Ther. 271 (3) (1994) 1483-1488.
-
(1994)
J. Pharmacol. Exp. Ther.
, vol.271
, Issue.3
, pp. 1483-1488
-
-
Mehrke, G.1
Zong, X.G.2
Flockerzi, V.3
Hofmann, F.4
-
14
-
-
0030861535
-
Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension
-
[14] Oparil S., Bernink P., Bursztyn M., Carney S., Kobrin I., Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension, Am. J. Cardiol. 80 (4B) (1997) 12C 19C.
-
(1997)
Am. J. Cardiol.
, vol.80
, Issue.4 B
-
-
Oparil, S.1
Bernink, P.2
Bursztyn, M.3
Carney, S.4
Kobrin, I.5
-
15
-
-
0032496879
-
Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
-
[15] Mullins M.E., Horowitz B.Z., Linden D.H., Smith G.W., Norton R.L., Stump J., Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers, JAMA (J. Am. Med. Assoc.) 280 (2) (1998) 157-158.
-
(1998)
JAMA (J. Am. Med. Assoc.)
, vol.280
, Issue.2
, pp. 157-158
-
-
Mullins, M.E.1
Horowitz, B.Z.2
Linden, D.H.3
Smith, G.W.4
Norton, R.L.5
Stump, J.6
-
16
-
-
1542640490
-
Rhabdomyolysis due to interaction of simvastatin with mibefradil
-
[16] Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., Haefeli W.E., Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet 351 (9120) (1998) 1929 1930.
-
(1998)
Lancet
, vol.351
, Issue.9120
, pp. 1929
-
-
Schmassmann-Suhijar, D.1
Bullingham, R.2
Gasser, R.3
Schmutz, J.4
Haefeli, W.E.5
-
17
-
-
85077295695
-
Announce new drug-interaction warnings for mibefradil [news]
-
[17] Roche, FDA announce new drug-interaction warnings for mibefradil [news]. Am J. Health Syst. Pharm. 55 (3) (1998) 210.
-
(1998)
Am J. Health Syst. Pharm.
, vol.55
, Issue.3
, pp. 210
-
-
Roche, F.D.A.1
-
18
-
-
0032551211
-
What lessons can be learnt from withdrawal of mibefradil from the market?
-
[18] Po A.L., Zhang W.Y., What lessons can be learnt from withdrawal of mibefradil from the market?, Lancet 351 (9119) (1998) 1829 1830.
-
(1998)
Lancet
, vol.351
, Issue.9119
, pp. 1829
-
-
Po, A.L.1
Zhang, W.Y.2
-
19
-
-
0027361358
-
A new series of imidazolones: Highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists
-
[19] Bernhart C.A., Perreaut P.M., Ferrari B.P., Muneaux Y.A., Assens J.L., Clement J., Haudricourt F., Muneaux C.F., Taillades J.E., Vignal M.A. et al., A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists, J. Med. Chem. 36 (22) (1993) 3371-3380.
-
(1993)
J. Med. Chem.
, vol.36
, Issue.22
, pp. 3371-3380
-
-
Bernhart, C.A.1
Perreaut, P.M.2
Ferrari, B.P.3
Muneaux, Y.A.4
Assens, J.L.5
Clement, J.6
Haudricourt, F.7
Muneaux, C.F.8
Taillades, J.E.9
Vignal, M.A.10
-
20
-
-
0026628079
-
Pharmacology of nonpeptide angiotensin II receptor antagonists
-
[20] Smith R.D., Chiu A.T., Wong P.C., Herblin W.F., Timmermans P.B., Pharmacology of nonpeptide angiotensin II receptor antagonists, Annu. Rev. Pharmacol. Toxicol. 32 (1992) 135-165.
-
(1992)
Annu. Rev. Pharmacol. Toxicol.
, vol.32
, pp. 135-165
-
-
Smith, R.D.1
Chiu, A.T.2
Wong, P.C.3
Herblin, W.F.4
Timmermans, P.B.5
-
21
-
-
0030480760
-
Angiotensin receptors
-
[21] Unger T., Chung O., Csikos T., Culman J., Gallinat S., Gohlke P., Höhle S., Meffert S., Stoll M., Stroth U., Zhu Y.Z., Angiotensin receptors, J. Hypertens. 14 (suppl. 4) (1996) S95-S103.
-
(1996)
J. Hypertens.
, vol.14
, Issue.SUPPL. 4
-
-
Unger, T.1
Chung, O.2
Csikos, T.3
Culman, J.4
Gallinat, S.5
Gohlke, P.6
Höhle, S.7
Meffert, S.8
Stoll, M.9
Stroth, U.10
Zhu, Y.Z.11
-
22
-
-
0031768054
-
Pharmacology of angiotensin receptors and AT1 receptor blockers
-
[22] Chung O., Unger T., Pharmacology of angiotensin receptors and AT1 receptor blockers, Basic Res. Cardiol. 93 (suppl. 2) (1998) 15-23.
-
(1998)
Basic Res. Cardiol.
, vol.93
, Issue.SUPPL. 2
, pp. 15-23
-
-
Chung, O.1
Unger, T.2
-
23
-
-
0008890571
-
Physiological and pharmacological implications of AT1 vs. AT2 receptors
-
[23] Chung O., Stoll M., Unger T., Physiological and pharmacological implications of AT1 vs. AT2 receptors, Blood Pressure 5 (1996) 42-47.
-
(1996)
Blood Pressure
, vol.5
, pp. 42-47
-
-
Chung, O.1
Stoll, M.2
Unger, T.3
-
24
-
-
0031427248
-
Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues
-
[24] Johnston C.I., Naitoh M., Burrell L.M., Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues, J. Hypertens. Suppl. 15 (7) (1997) S3-S6.
-
(1997)
J. Hypertens. Suppl.
, vol.15
, Issue.7
-
-
Johnston, C.I.1
Naitoh, M.2
Burrell, L.M.3
-
25
-
-
0029743723
-
A new class of antihypertensive therapy: Angiotensin II receptor antagonists
-
[25] Ellis M.L., Patterson J.H., A new class of antihypertensive therapy: angiotensin II receptor antagonists, Pharmacotherapy 16 (5) (1996) 849-860.
-
(1996)
Pharmacotherapy
, vol.16
, Issue.5
, pp. 849-860
-
-
Ellis, M.L.1
Patterson, J.H.2
-
26
-
-
0029777512
-
An in-patient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension
-
[26] Byyny R.L., Merrill D.D., Bradstreet T.E., Sweet C.S., An in-patient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension, Cardiovasc. Drugs Ther. 10 (3) (1996) 313-319.
-
(1996)
Cardiovasc. Drugs Ther.
, vol.10
, Issue.3
, pp. 313-319
-
-
Byyny, R.L.1
Merrill, D.D.2
Bradstreet, T.E.3
Sweet, C.S.4
-
27
-
-
0028935595
-
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
-
[27] Goldberg A.I., Dunlay M.C., Sweet C.S., Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension, Am. J. Cardiol. 75 (12) (1995) 793-795.
-
(1995)
Am. J. Cardiol.
, vol.75
, Issue.12
, pp. 793-795
-
-
Goldberg, A.I.1
Dunlay, M.C.2
Sweet, C.S.3
-
28
-
-
0030798211
-
Clinical safety and tolerability of losartan
-
[28] Weber M., Clinical safety and tolerability of losartan, Clin. Ther. 19 (4) (1997) 604-616.
-
(1997)
Clin. Ther.
, vol.19
, Issue.4
, pp. 604-616
-
-
Weber, M.1
-
29
-
-
0029932496
-
Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
-
[29] Goa K.L., Wagstaff A.J., Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension, Drugs 51 (5) (1996) 820-845.
-
(1996)
Drugs
, vol.51
, Issue.5
, pp. 820-845
-
-
Goa, K.L.1
Wagstaff, A.J.2
-
30
-
-
0030902115
-
Randomised trial of losartan versus captopril in patients over 65 with heart failure
-
[30] Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., Deedwania P.C., Ney D.E., Snavely D.B., Chang P.I., Randomised trial of losartan versus captopril in patients over 65 with heart failure, Lancet 349 (9054) (1997) 747-752.
-
(1997)
Lancet
, vol.349
, Issue.9054
, pp. 747-752
-
-
Pitt, B.1
Segal, R.2
Martinez, F.A.3
Meurers, G.4
Cowley, A.J.5
Thomas, I.6
Deedwania, P.C.7
Ney, D.E.8
Snavely, D.B.9
Chang, P.I.10
-
31
-
-
0030338821
-
Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension
-
[31] Mallion J.M., Goldberg A.I., Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension, Blood Press Suppl. 2 (1996) 82-86.
-
(1996)
Blood Press Suppl.
, vol.2
, pp. 82-86
-
-
Mallion, J.M.1
Goldberg, A.I.2
-
32
-
-
9044220224
-
Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
-
[32] Tikkanen I., Omvik P., Jensen H.A., Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension, J. Hypertens. 13 (11) (1995) 1343-1351.
-
(1995)
J. Hypertens.
, vol.13
, Issue.11
, pp. 1343-1351
-
-
Tikkanen, I.1
Omvik, P.2
Jensen, H.A.3
-
33
-
-
0029058333
-
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
-
[33] Dahlof B., Keller S.E., Makris L., Goldberg A.I., Sweet C.S., Lim N.Y., Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension, Am. J. Hypertens. 8 (6) (1995) 578-583.
-
(1995)
Am. J. Hypertens.
, vol.8
, Issue.6
, pp. 578-583
-
-
Dahlof, B.1
Keller, S.E.2
Makris, L.3
Goldberg, A.I.4
Sweet, C.S.5
Lim, N.Y.6
-
34
-
-
0029153169
-
Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension
-
[34] Chan J.C., Critchley J.A., Lappe J.T., Raskin S.J., Snavely D., Goldberg A.I., Sweet C.S., Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension, J. Hum. Hypertens. 9 (9) (1995) 765-771.
-
(1995)
J. Hum. Hypertens.
, vol.9
, Issue.9
, pp. 765-771
-
-
Chan, J.C.1
Critchley, J.A.2
Lappe, J.T.3
Raskin, S.J.4
Snavely, D.5
Goldberg, A.I.6
Sweet, C.S.7
-
35
-
-
0029065095
-
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
-
[35] Gradman A.H., Arcuri K.E., Goldberg A.I., Ikeda L.S., Nelson E.B., Snavely D.B., Sweet C.S., A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension, Hypertension 25 (6) (1995) 1345-1350.
-
(1995)
Hypertension
, vol.25
, Issue.6
, pp. 1345-1350
-
-
Gradman, A.H.1
Arcuri, K.E.2
Goldberg, A.I.3
Ikeda, L.S.4
Nelson, E.B.5
Snavely, D.B.6
Sweet, C.S.7
-
36
-
-
0031017243
-
Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension
-
[36] Ikeda L.S., Harm S.C., Arcuri K.E., Goldberg A.I., Sweet C.S., Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension, Blood Press. 6 (1) (1997) 35-43.
-
(1997)
Blood Press
, vol.6
, Issue.1
, pp. 35-43
-
-
Ikeda, L.S.1
Harm, S.C.2
Arcuri, K.E.3
Goldberg, A.I.4
Sweet, C.S.5
-
37
-
-
0025215247
-
Power and sample size calculations. A review and computer program
-
[37] Dupont W.D., Plummer W.D., Power and sample size calculations. A review and computer program, Controlled Clinical Trials 11 (1990) 116-128.
-
(1990)
Controlled Clinical Trials
, vol.11
, pp. 116-128
-
-
Dupont, W.D.1
Plummer, W.D.2
-
38
-
-
0031801116
-
Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension
-
[38] Oparil S., Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension, Am. J. Hypertens. 11 (1998) 88S-94S.
-
(1998)
Am. J. Hypertens.
, vol.11
-
-
Oparil, S.1
-
39
-
-
0031081764
-
The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension
-
[39] Lacourciere Y., Poirier L., Lefebvre J., Archambault F., Dalle Ave S., Ward C., Lindberg E., The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension, Am. J. Hypertens. 10 (2) (1997) 189-196.
-
(1997)
Am. J. Hypertens.
, vol.10
, Issue.2
, pp. 189-196
-
-
Lacourciere, Y.1
Poirier, L.2
Lefebvre, J.3
Archambault, F.4
Dalle Ave, S.5
Ward, C.6
Lindberg, E.7
-
40
-
-
0030751117
-
Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension
-
[40] McIntyre M., Caffe S.E., Michalak R.A., Reid J.L., Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension, Pharmacol. Ther. 74 (2) (1997) 181-194.
-
(1997)
Pharmacol. Ther.
, vol.74
, Issue.2
, pp. 181-194
-
-
McIntyre, M.1
Caffe, S.E.2
Michalak, R.A.3
Reid, J.L.4
-
41
-
-
0027363881
-
Human blood pressure determination by sphygmomanometry
-
[41] Perloff D., Arim C., Flack J., Frohlich E.D., Hill M., McDonald M., Morgenstern B.Z., Human blood pressure determination by sphygmomanometry, Circulation 88 (1993) 2460-2470.
-
(1993)
Circulation
, vol.88
, pp. 2460-2470
-
-
Perloff, D.1
Arim, C.2
Flack, J.3
Frohlich, E.D.4
Hill, M.5
McDonald, M.6
Morgenstern, B.Z.7
-
42
-
-
0026559238
-
American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmamanometry
-
[42] American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmamanometry, Am. J. Hypertens. 5 (1992) 207-209.
-
(1992)
Am. J. Hypertens.
, vol.5
, pp. 207-209
-
-
-
43
-
-
0027483749
-
The guidelines for the management of mild hypertension: Memorandum from a WHO ISH meeting
-
[43] Zanchetti A., Chalmers J.P., Arakawa K., Gyarfas I., Hamet P., Hansson L. et al., The guidelines for the management of mild hypertension: memorandum from a WHO ISH meeting, Blood Press. 2 (2) (1993) 86-100.
-
(1993)
Blood Press
, vol.2
, Issue.2
, pp. 86-100
-
-
Zanchetti, A.1
Chalmers, J.P.2
Arakawa, K.3
Gyarfas, I.4
Hamet, P.5
Hansson, L.6
-
44
-
-
0025043248
-
Blood pressure and coronary heart disease
-
[44] Collins R., Peto R., Godwin J., MacMahon S., Blood pressure and coronary heart disease, Lancet 336 (8711) (1990) 370-371.
-
(1990)
Lancet
, vol.336
, Issue.8711
, pp. 370-371
-
-
Collins, R.1
Peto, R.2
Godwin, J.3
MacMahon, S.4
-
45
-
-
0028942349
-
Blood pressure effects of the angiotensin II receptor blocker, losartan
-
[45] Weber M.A., Byyny R.L., Pratt J.H., Faison E.P., Snavely D.B., Goldberg A.I., Nelson E.B., Blood pressure effects of the angiotensin II receptor blocker, losartan, Arch. Intern. Med. 155 (4) (1995) 405-411.
-
(1995)
Arch. Intern. Med.
, vol.155
, Issue.4
, pp. 405-411
-
-
Weber, M.A.1
Byyny, R.L.2
Pratt, J.H.3
Faison, E.P.4
Snavely, D.B.5
Goldberg, A.I.6
Nelson, E.B.7
-
46
-
-
0027516115
-
Influence of heart rate on mortality among persons with hypertension: The Framingham Study
-
[46] Gillman M.W., Kannel W.B., Belanger A., D'Agostino R.B., Influence of heart rate on mortality among persons with hypertension: the Framingham Study, Am. Heart J. 125 (1993) 1148-1154.
-
(1993)
Am. Heart J.
, vol.125
, pp. 1148-1154
-
-
Gillman, M.W.1
Kannel, W.B.2
Belanger, A.3
D'Agostino, R.B.4
|